Thursday, August 11, 2022


Trinity Life Sciences Acquires Vancery’s Customer Research Technology

Latest Posts

New Study Highlights Superior Efficacy of At-home Dry EEG assessment Compared to Lab-based Monitoring

Results indicate that easy-to-use task-driven EEG can yield clinical-grade data in large-scale, real-world investigations in neuroscience with extremely high adherence rates.

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it signed an asset purchase agreement for the acquisition of Vancery’s customer research technology.

The investment expands Trinity’s insights and analytics product offerings, allowing the company to better connect with healthcare professionals to inform commercial strategy for its clients. The new technology will improve primary market research in the life sciences by integrating advanced research methods with an enhanced respondent experience to drive higher quality insights.

“We are thrilled to bring the sophisticated customer research technology that Vancery built to the healthcare space,” said Aparna Deshpande, PhD, Senior Partner, Insights. “Now, more than ever, payer, patient and healthcare provider research are critical in making sure treatments are available ASAP to those in need.”

Besides the technology acquisition, a team of experts from Vancery will join Trinity to continue to support and transform the software for use in healthcare.

“I am so proud of what the Vancery team has built and delighted that Trinity will bring our technology and vision to the next level,” said Gunnar Gregory, CEO, Vancery. “With Trinity, our unique technologies will help incorporate qualitative and quantitative research into their life science clients’ daily decision-making.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine